(NewsDirect)
Valeo Pharma CEO Steve Saviuk joined SteveDarling from Proactive to share news the company has once again seenrecord numbers as it unveils its second-quarter financials. Thenumbers include the 6th consecutive quarter of revenue growth at $13.6million, up 184% over 2Q 2022.
Saviuk telling Proactive the number company also saw 6thconsecutive quarter of adjusted EBITDA loss reduction at $1.7 million,which is a 53% improvement.
Enerzair and Atectura continue to perform well with totalprescriptions for the 12 months ending April 30, 2023 exceeding45,000, up 654% over April 30, 2022.
Looking ahead, the companyprojects revenues to exceed $60 million for the year, expectingcontinued growth in the third quarter.
ContactDetails
Proactive Investors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.